New York Stock Exchange & AstraZeneca

New York Stock Exchange: The New York Stock Exchange provides daily pre-market updates and hosts the listings of various companies, including the significant transfer of AstraZeneca.

AstraZeneca: AstraZeneca celebrated its February transfer to the New York Stock Exchange, which was the largest transfer by market capitalization in the exchange's history, indicating a positive move for the company's market presence.

New York Stock Exchange: The New York Stock Exchange benefits from AstraZeneca's direct listing, which was completed in June, and could see increased activity if the merger proceeds.

AstraZeneca: AstraZeneca is the initiator of the merger talks, seeking to expand its US presence. Its shares fell over 7% on the news, reflecting investor skepticism about the deal's value and execution risk.

New York Stock Exchange: AstraZeneca is listed on New York Stock Exchange; the deal may influence stock price.

AstraZeneca: AstraZeneca expands its lung cancer portfolio with a novel oral EGFR inhibitor, complementing existing drugs like Tagrisso. The deal involves a $600M upfront payment and potential milestones, but does not affect 2026 guidance.

New York Stock Exchange: AstraZeneca's ADS trades on NYSE; the exchange is not directly affected.

AstraZeneca: AstraZeneca's stock fell 5.7% after the trial failure; it faces investor investigations and potential legal liability.

New York Stock Exchange: Hosted trading, with record highs.

AstraZeneca: Investors punished the stock over merger talks with Bristol Myers Squibb.